Ascendis Pharma A/S (ASND) director discloses 9,160-share warrant position
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Ascendis Pharma A/S director Jean Jacques Bienaimé filed an initial ownership report showing a warrant position rather than common shares. He directly holds warrants exercisable for 9,160 Ordinary Shares, with an exercise price of $172.35 per share and expiration on June 10, 2035. The warrants vest 25% on June 10, 2026 and then in 36 equal monthly installments. The filing also indicates he holds no Ordinary Shares directly as of the reporting date, and notes that the position includes American Depositary Shares, with each ADS representing one Ordinary Share.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
BIENAIME JEAN JACQUES
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 9,160 shares (Direct);
Ordinary Shares — 0 shares (Direct)
Footnotes (1)
- Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.
Key Figures
Underlying warrant shares: 9,160 shares
Warrant exercise price: $172.35 per share
Warrant expiration date: June 10, 2035
+3 more
6 metrics
Underlying warrant shares
9,160 shares
Ordinary Shares underlying warrants, direct holding
Warrant exercise price
$172.35 per share
Exercise price for Ordinary Shares under warrants
Warrant expiration date
June 10, 2035
Expiration date of warrants over Ordinary Shares
Initial vesting date
June 10, 2026
25% of warrants vest on this date
Remaining vesting schedule
36 monthly installments
Post-initial vesting pattern for remaining warrants
Ordinary Shares held
0 shares
Total Ordinary Shares directly owned after reporting
Key Terms
American Depositary Shares ("ADS"), Warrants, Ordinary Shares, vesting
4 terms
Warrants financial
"The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments."
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
vesting financial
"The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider position did Ascendis Pharma (ASND) director Jean Jacques Bienaimé report on Form 3?
Jean Jacques Bienaimé reported holding warrants over 9,160 Ordinary Shares of Ascendis Pharma A/S. These warrants represent his initial disclosed beneficial ownership and include equivalent American Depositary Shares (ADS), with each ADS corresponding to one Ordinary Share of the company.
What is the exercise price of the warrants reported by Ascendis Pharma (ASND) director Bienaimé?
The warrants held by Jean Jacques Bienaimé are exercisable at $172.35 per Ordinary Share. This exercise price defines the cost per share if the warrants are exercised and is a key term governing the economic value of his derivative position in Ascendis Pharma A/S.
When do Jean Jacques Bienaimé’s Ascendis Pharma (ASND) warrants vest and expire?
Bienaimé’s warrants vest 25% on June 10, 2026, with the remaining portion vesting in 36 equal monthly installments. The warrants carry an expiration date of June 10, 2035, establishing a long-dated timeframe during which he may choose to exercise this derivative position.